UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Diabetes, obesity & metabolism, 2014-04, Vol.16 (4), p.366-375

2014

Link zum Volltext

Verfügbarkeit prüfen

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

Diabetic medicine, 2016-04, Vol.33 (4), p.471-477

2016

Link zum Volltext

Verfügbarkeit prüfen

What is innovation in the area of medicines? The example of insulin and diabetes

Diabetic medicine, 2019-12, Vol.36 (12), p.1528-1529

2019

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK

Journal of medical economics, 2015-01, Vol.18 (1), p.56-68

2015

Link zum Volltext

Verfügbarkeit prüfen

Development and validation of a cost-utility model for Type 1 diabetes mellitus

Diabetic medicine, 2015-08, Vol.32 (8), p.1023-1035

2015

Link zum Volltext

Verfügbarkeit prüfen

Diminishing Marginal Disutility of Hypoglycaemic Events

Value in health, 2013-11, Vol.16 (7), p.A445-A445

2013

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Link zum Volltext

Verfügbarkeit prüfen

Benchmarks for interpretation of score differences on the SF-36 health survey

Value in health, 2013-05, Vol.16 (3), p.A35-A35

2013

Link zum Volltext

Verfügbarkeit prüfen

PDB19 A Systematic Review of Recent Data Describing the Risk of Complications in Type 1 Diabetes Mellitus Patients

Value in health, 2012-11, Vol.15 (7), p.A496-A497

2012

Link zum Volltext

Verfügbarkeit prüfen

PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT)

Value in health, 2019-11, Vol.22, p.S583-S583

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the long-term cost-effectiveness of introducing a smart insulin pen in standard-of-care treatment of type 1 diabetes in Sweden

Diabetologia, 2020, Vol.63 (Suppl. 1), p.S381

2020

Link zum Volltext

Verfügbarkeit prüfen

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease

Alzheimer's research & therapy, 2024-02, Vol.16 (1), p.48-48

2024

Link zum Volltext

Verfügbarkeit prüfen

PDB27 - Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Value in health, 2017-10, Vol.20 (9), p.A478-A479

2017

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Value in health, 2017-10, Vol.20 (9), p.A478-A479

2017

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

Current medical research and opinion, 2017-04, Vol.33 (4), p.647-655

2017

Link zum Volltext

Verfügbarkeit prüfen

Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Value in health, 2016-11, Vol.19 (7), p.A673-A673

2016

Link zum Volltext

Verfügbarkeit prüfen

PDB48 - Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Value in health, 2016-11, Vol.19 (7), p.A673-A673

2016

Link zum Volltext

Verfügbarkeit prüfen

Income-related inequality in utilization of health services in Denmark: Evidence from Funen County

Scandinavian journal of public health, 2006-10, Vol.34 (5), p.462-471

GUNDGAARD, JENS

2006

Link zum Volltext

Verfügbarkeit prüfen

PDB43 - Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Value in health, 2016-11, Vol.19 (7), p.A672-A672

2016

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Value in health, 2016-11, Vol.19 (7), p.A672-A672

2016

Link zum Volltext

Verfügbarkeit prüfen

Income related inequality in prescription drugs in Denmark

Pharmacoepidemiology and drug safety, 2005-05, Vol.14 (5), p.307-317

Gundgaard, Jens

2005

Link zum Volltext

Verfügbarkeit prüfen

PDB81 - Diminishing Marginal Disutility of Hypoglycaemic Events

Value in health, 2013-11, Vol.16 (7), p.A445-A445

2013

Link zum Volltext

Verfügbarkeit prüfen

PDB64 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Link zum Volltext

Verfügbarkeit prüfen

PDB65 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(41)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(16)
Diabetes
(11)
Internal Medicine
(11)
Adult
(9)
Female
(9)
Hypoglycemia
(8)
Male
(8)
Cost-Benefit Analysis
(7)
Insulin
(7)
Hypoglycemic Agents - Economics
(6)
Middle Aged
(6)
Public, Environmental & Occupational Health
(6)
Cost Analysis
(5)
Cost-Effectiveness
(5)
Endocrinology & Metabolism
(5)
Hypoglycemic Agents - Therapeutic Use
(5)
Insulin, Long-Acting - Economics
(5)
Medicin Och Hälsovetenskap
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

What is innovation in the area of medicines? The example of insulin and diabetes

Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK

Development and validation of a cost-utility model for Type 1 diabetes mellitus

Diminishing Marginal Disutility of Hypoglycaemic Events

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Benchmarks for interpretation of score differences on the SF-36 health survey

PDB19 A Systematic Review of Recent Data Describing the Risk of Complications in Type 1 Diabetes Mellitus Patients

PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT)

Evaluating the long-term cost-effectiveness of introducing a smart insulin pen in standard-of-care treatment of type 1 diabetes in Sweden

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease

PDB27 - Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

PDB48 - Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Income-related inequality in utilization of health services in Denmark: Evidence from Funen County

PDB43 - Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Income related inequality in prescription drugs in Denmark

PDB81 - Diminishing Marginal Disutility of Hypoglycaemic Events

PDB64 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

PDB65 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Suchergebnisse filtern